Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Guidant favors latest Boston Scientific offer
The new Boston Scientific offer represents a valuation of $80 per Guidant share, which would take the form of $42 cash and $38 in Boston Scientific stock. “We
The new Boston Scientific offer represents a valuation of $80 per Guidant share, which would take the form of $42 cash and $38 in Boston Scientific stock. “We
This fall in profit is partly due to a 9% decrease in overall revenues from $832 million to $758 million. Sales in the quarter included $486 million for
This new candidate, a p38 kinase inhibitor, represents the second compound to advance to the clinic from the partnership between the companies. Under the terms of the collaboration
The peptides, TR-291144 and TR-290999, first synthesized at Trimeris, are distinct compounds derived from HR2 sequences of HIV. In connection with this event, Trimeris will receive a payment
The primary objective of the study is overall response rate, including patients with complete responses and partial responses. Secondary objectives of the study include, time-to-progression, duration-of-response and overall
Peramivir is an influenza neuraminidase inhibitor that, in preclinical studies, has shown potent, broad spectrum activity against multiple strains of flu, including the H5N1 virus. On December 22,
Alrx IM is derived from indomethacin, a non-steroidal anti-inflammatory drug (NSAID) normally administered in capsular form for the treatment of inflammatory diseases such as arthritis, muscle pain, and
The open-label, dose-escalation trial is designed to evaluate tolerability and pharmacokinetics of the drug following oral administration to patients with advanced cancer. In addition, the trial is designed
The collaboration includes an investigation of Acadia’s selective m1 agonists for treatment of schizophrenia and other neuropsychiatric disorders. Muscarinic receptors respond to the neurotransmitter acetylcholine and compounds that
Since March 2004, CombiMatrix has been awarded a $5.9 million contract, a $2.1 million contract that is currently in process, and the latest allocation of $2.4 million for